The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.